Skip to main content
Premium Trial:

Request an Annual Quote

Andrew Firlik, James Gourzis, David Mason, Denis Burger

Premium


The Sprout Group
this week named Andrew Firlik as partner for healthcare technology investments.

According to the Sprout Group, Firlik was most recently principal at Canaan Partners. Prior to this he was co-founder and principal of Cortex Consulting. He is also a co-founder of Seattle-based medical device company Northstar Neuroscience.

The Sprout Group currently manages about $2 billion in committed capital, and focuses on companies in the healthcare and information technology sectors. Among the firms in which it invests is Sirna Therapeutics.


AVI BioPharma said this week that it has signed on James Gourzis as a strategic consultant.

AVI also said that its senior vice president for clinical development and regulatory affairs, David Mason, has resigned from the company and moved east in order to “pursue opportunities closer to his family.”

According to AVI, Gourzis has been acting as a consultant to a number of biotechnology and medical device companies, providing advice on scientific, strategic, and regulatory issues. Prior to this, he was an executive with contract research organization Parexel International.

“We are pleased to have … Gourzis join our team, as his extensive product development and regulatory experience are well-suited to AVI’s strategic goals for 2004 and beyond,” AVI CEO Denis Burger said in a statement. “As we continue to advance our clinical development programs, James’ licensing experience and FDA knowledge will bring additional strength to the execution of our corporate strategies.”

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.